197 related articles for article (PubMed ID: 30270681)
1. Cyclophosphamide eradicates murine immunogenic tumor coding for a non-self-antigen and induces antitumor immunity.
Salem ML; El-Naggar SA; Mahmoud HA; Elgharabawy RM; Bader AM
Int J Immunopathol Pharmacol; 2018; 32():2058738418796591. PubMed ID: 30270681
[TBL] [Abstract][Full Text] [Related]
2. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.
Zhou F; Rouse BT; Huang L
Cancer Res; 1992 Nov; 52(22):6287-91. PubMed ID: 1384958
[TBL] [Abstract][Full Text] [Related]
4. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
5. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
[TBL] [Abstract][Full Text] [Related]
7. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.
Schiavoni G; Mattei F; Di Pucchio T; Santini SM; Bracci L; Belardelli F; Proietti E
Blood; 2000 Mar; 95(6):2024-30. PubMed ID: 10706870
[TBL] [Abstract][Full Text] [Related]
9. Immune selection of tumor cells in TCR β-chain transgenic mice.
Silaeva YY; Grinenko TS; Vagida MS; Kalinina AA; Khromykh LM; Kazansky DB
J Immunotoxicol; 2014 Oct; 11(4):393-9. PubMed ID: 24308870
[TBL] [Abstract][Full Text] [Related]
10. Cell death induced by cytotoxic CD8
Jaime-Sanchez P; Uranga-Murillo I; Aguilo N; Khouili SC; Arias MA; Sancho D; Pardo J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32241808
[TBL] [Abstract][Full Text] [Related]
11. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism.
Stremmel C; Greenfield EA; Howard E; Freeman GJ; Kuchroo VK
J Exp Med; 1999 Mar; 189(6):919-30. PubMed ID: 10075975
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
13. Notch2 signaling is required for potent antitumor immunity in vivo.
Sugimoto K; Maekawa Y; Kitamura A; Nishida J; Koyanagi A; Yagita H; Kojima H; Chiba S; Shimada M; Yasutomo K
J Immunol; 2010 May; 184(9):4673-8. PubMed ID: 20351182
[TBL] [Abstract][Full Text] [Related]
14. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.
Manrique SZ; Dominguez AL; Mirza N; Spencer CD; Bradley JM; Finke JH; Lee JJ; Pease LR; Gendler SJ; Cohen PA
Oncotarget; 2016 Jul; 7(28):42919-42942. PubMed ID: 27341020
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
Ding ZC; Lu X; Yu M; Lemos H; Huang L; Chandler P; Liu K; Walters M; Krasinski A; Mack M; Blazar BR; Mellor AL; Munn DH; Zhou G
Cancer Res; 2014 Jul; 74(13):3441-53. PubMed ID: 24780756
[TBL] [Abstract][Full Text] [Related]
16. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
17. Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice.
Ibrahim HM; Abdel Ghaffar FR; El-Elaimy IA; Gouida MS; Abd El Latif HM
Biomed Pharmacother; 2018 Oct; 106():43-49. PubMed ID: 29945116
[TBL] [Abstract][Full Text] [Related]
18. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
19. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
[TBL] [Abstract][Full Text] [Related]
20. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]